Cancer Research Horizons collaborates with Diamond to accelerate drug discovery
Cancer Research Horizons has teamed up with Diamond Light Source to drive the discovery of new cancer treatments.
List view / Grid view
News
NKTR-255 shows positive results in lymphoma therapy
Nektar Therapeutics' NKTR-255 improves CAR-T therapy outcomes in lymphoma patients. Find out how this development could impact cancer treatment.
Refeyn launches software platform to automate mass photometry workflows
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
Novartis licenses innovative treatment for Huntington’s disease
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
Small molecule drug discovery market projected to hit $106 billion by 2031
The global small molecule drug discovery market is set for significant growth. Explore the key factors driving this expansion, from rising R&D investments to the increasing role of AI and CROs.
Key enzyme discovery marks a step forward in Alzheimer’s treatment
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
Eurofins expands to China to strengthen local expertise
Eurofins Healthcare Assurance is expanding into China to better serve key industries with local expertise. This move strengthens their commitment to quality assurance and regulatory services on a global scale.
E. coli alters ribosomes to survive antibiotic treatment
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
Halozyme’s €2 billion bid to transform drug discovery
By acquiring Evotec, Halozyme aims to enhance drug discovery and delivery, driving substantial growth in the pharmaceutical sector.
FDA greenlights AI-developed drug targeting solid tumors
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
New DNA nanostructures set to transform cancer treatment
A University of Sydney study reveals how DNA origami can build programmable nanostructures, with promising applications in targeted drug delivery and nanorobotics.
CNIC identifies key mechanism in fat cells to combat obesity
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
New CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
Metrion Biosciences appoints Lee Patterson as CEO
Metrion Biosciences is set to accelerate its global expansion and enhance its leadership in ion channel drug discovery services.
Breakthrough trial offers new hope for cystic fibrosis patients
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
